MISSION^® LentiPlex^® Pooled shRNA Library Screening in Mammalian Cells

The MISSION LentiPlex Human shRNA Pooled Library is a genome-wide lentiviral pool produced using a proprietary process. The library consists of over 75,000 shRNA constructs from the TRC collection targeting 15,000+ human genes¹. Each library is tested for shRNA representation before product release to ensure robust library coverage. The library is provided in a ready-to-use lentiviral format at titers of at least 5 x 108 TU/ml via p24 assay and is pre-divided into ten subpools of approximately 8,000 shRNA constructs each. Amplification and sequencing primers are also provided for downstream target identification.

Previous studies established a synergistic antitumor activity of TRAIL when combined with Paclitaxel in A549 cells, a human lung carcinoma cell line^2,3. In this study we demonstrate the application of a pooled LentiPlex shRNA library to rapidly conduct a positive selection screen for genes involved in the cytotoxicity of A549 cells when exposed to TRAIL and Paclitaxel. One barrier often encountered with high-throughput screens is the cost and difficulty in deconvolution; we also detail a cost-effective polyclonal approach utilizing traditional sequencing.

To learn more, read the Biofiles article on Pooled Lentiviral shRNA Screens to Identify Essential Cancer Pathways.

View the product information at MISSION LentiPlex Pooled shRNA Libraries.

References

1. Root, D., et al. Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods. 3(9), 715 (2006).
2. Fan, Q., et al. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo. Cancer Chemother Pharmacol. 55, 189 (2005).
3. Ji, D., et al. A screen of shRNAs targeting tumor suppressor genes to identify factors involved in A549 paclitaxel sensitivity. Oncology Reports. 18, 1499 (2007).